Opioid Use Disorders in Adolescents-Slides

Slides

Pdf Summary

This presentation by Dr. Lee Trope addresses the opioid epidemic among young people, focusing on epidemiology, drug supply changes, screening, treatment, and harm reduction. Teen overdose deaths, especially among 15-19-year-olds, have surged mainly due to fentanyl’s potency; it is implicated in 90% of teen opioid overdose deaths, often combined with other substances. Most overdoses occur at home, frequently with others present, yet naloxone (Narcan) administration is still underutilized.<br /><br />Young people often acquire opioids via counterfeit pills purchased on social media, with about 60% containing lethal fentanyl doses. Opioid use disorder (OUD) typically begins in adolescence or early adulthood, with rapid escalation and high overdose risk. Dependence can develop after daily use for only 2-3 weeks.<br /><br />Screening tools like S2BI or SBIRT have high accuracy in identifying substance use disorders in youth. Evidence-based treatment emphasizes Medication-Assisted Treatment (MAT), particularly buprenorphine, a partial opioid agonist shown to reduce overdose and mortality. However, only 5% of adolescents with OUD receive timely treatment due to workforce and logistical barriers. Recent regulatory changes have eased buprenorphine prescribing restrictions.<br /><br />Harm reduction principles urge nonjudgmental care, offering naloxone to all people who use opioids, providing additional health services, and using destigmatizing language. Stigma in healthcare exacerbates the epidemic and hinders treatment access.<br /><br />In summary, escalating fentanyl-related teen overdoses necessitate widespread screening, improved access to medications like buprenorphine, and robust harm reduction efforts. Addressing these elements with a public health approach can save young lives and support recovery.

Keywords

opioid epidemic

teen overdose deaths

fentanyl potency

counterfeit pills

opioid use disorder

screening tools

Medication-Assisted Treatment

buprenorphine

harm reduction

stigma in healthcare